The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
As a single agent for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapyEMILIA
Breast Cancer
Breast Cancer
HER2+
EMILIA
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Pertuzumab
Trastuzumab + docetaxel
Trastuzumab + docetaxel + placebo
HER2-positive locally recurrent unresectable or metastatic breast cancer with no prior anti-HER2 therapy or ChT for metastatic diseaseCLEOPATRA
Breast Cancer
Breast Cancer
HER2+
CLEOPATRA
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Lapatinib
Trastuzumab
Lapatinib
Treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with trastuzumab for patients with HR- metastatic disease that has progressed on prior trastuzumab therapy of therapies in combination with ChTEGF104900
Breast Cancer
Breast Cancer
HER2+ HR-
EGF104900
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Palbociclib
Fulvestrant
Fulvestrant + placebo
Patients with hormone receptor-positive, HER2-negative locally advanced or MBC who have received prior ETPALOMA-3
Breast Cancer
Breast Cancer
HR+ HER2-
PALOMA-3
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Palbociclib
Letrozole
Letrozole + placebo
Treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitorPALOMA-2
Breast Cancer
Breast Cancer
HR+ HER2-
PALOMA-2
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Palbociclib
Letrozole
Letrozole
Treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor.PALOMA-1/TRIO-18
Breast Cancer
Breast Cancer
HR+ HER2-
PALOMA-1/TRIO-18
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Ribociclib
Letrozole
Letrozole + placebo
Treatment of women with HR+, HER2 negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy. In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone‑releasing hormone (LHRH) agonistMONALEESA-2
Breast Cancer
Breast Cancer
HR+ HER2-
MONALEESA-2
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Lapatinib
Capecitabine
Capecitabine
Treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic settingEGF100151
Breast Cancer
Breast Cancer
HER2+
EGF100151
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Bevacizumab
Paclitaxel
Paclitaxel
In combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancerE2100
Breast Cancer
Breast Cancer
-
E2100
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Everolimus
Exemestane
Exemestane + placebo
Treatment of HR+, HER2- advanced breast cancer, in combination with exemestane, in postmenpausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitorBOLERO-2
Breast Cancer
Breast Cancer
HR+ HER2-
BOLERO-2
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Eribulin
-
Treatment of physician's choice
As monotherapy for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and taxane unless patients were not suitable for these treatmentsEMBRACE
Breast Cancer
Breast Cancer
-
EMBRACE
2
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
2
Eribulin
-
Treatment of physician's choice
Treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatmentsStudy 305 & Study 301 (Pooled analysis)
Breast Cancer
Breast Cancer
HER2-
Study 305 & Study 301 (Pooled analysis)
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
1
Panitumumab
FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)
FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)
First-line treatment of patients with wild-type RAS mCRC PRIME
Treatment of patients with EGFR-expressing, RAS wild-type mCRC CRYSTAL
Gastrointestinal Cancers
Colorectal Cancer
EGFR-expressing RAS-WT
CRYSTAL
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Cetuximab
-
Best supportive care
Treatment of patients with EGFR-expressing, RAS wild-type mCRC in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan CO.17
Treatment of patients with metastatic carcinoma of the colon or rectum E3200
Gastrointestinal Cancers
Colorectal Cancer
-
E3200
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Panitumumab
-
Best supportive care
Treatment of patients with wild-type RAS mCRC after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing ChT regimens Study 20020408
Gastrointestinal Cancers
Colorectal Cancer
RAS-WT
Study 20020408
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Oxaliplatine
FOLFIRI + bevacizumab
FOLFIRI + bevacizumab
Treatment of patients with metastatic carcinoma of the colon or rectum TRIBE
Gastrointestinal Cancers
Colon and Rectal Cancer
-
TRIBE
2
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
2
Regorafenib
-
Placebo
Treatment of patients with mCRC who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based ChT, an anti-VEGF therapy and an anti-EGFR therapy CORRECT
Gastrointestinal Cancers
Colorectal Cancer
-
CORRECT
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
1
Aflibercept
FOLFIRI
FOLFIRI + placebo
Metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin containing regimenVELOUR
Gastrointestinal Cancers
Colorectal Cancer
-
VELOUR
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
1
Bevacizumab
Chemotherapy
Chemotherapy
Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based ChT for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen ML18147
Gastrointestinal Cancers
Colon and Rectal Cancer
-
ML18147
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
1
Epirubicin, 5-FU, Cisplatin + surgery
-
Surgery
Peri-operative resectable gastric or gastroesophageal junction adenocarcinomaMAGIC
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
-
MAGIC
A
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F1
A
5-FU, Cisplatin + surgery
-
Surgery
Peri-operative resectable gastric or gastroesophageal junction adenocarcinomaFRE-FNCLCC-94012
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
-
FRE-FNCLCC-94012
A
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F1
A
Ramucirumab
Paclitaxel
Paclitaxel + placebo
Advanced gastric cancer or gastroesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine ChTRAINBOW
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
-
RAINBOW
2
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
2
Ramucirumab
-
Placebo
Advanced gastric cancer or gastroesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine ChT, when treatment in combination with paclitaxel is not appropriateREGARD
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
-
REGARD
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
1
FOLFIRINOX
-
Gemcitabine
First-line metastatic pancreatic cancer in patients with good performance statusPRODIGE 4/ACCORD 11
Gastrointestinal Cancers
Pancreatic cancer
-
PRODIGE 4/ACCORD 11
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.